Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2015, Article ID 240750, 9 pages
http://dx.doi.org/10.1155/2015/240750
Clinical Study

Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2− Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study

1Analysis Group, Inc., Boston, MA 02199, USA
2Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA
3Analysis Group, Inc., New York, NY 10020, USA

Received 19 February 2015; Revised 23 April 2015; Accepted 24 April 2015

Academic Editor: Zsuzsanna Kahán

Copyright © 2015 Nanxin Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [12 citations]

The following is the list of published articles that have cited the current article.

  • Nanxin Li, Yanni Hao, Jipan Xie, Peggy L. Lin, Zhou Zhou, Yichen Zhong, James E. Signorovitch, and Eric Q. Wu, “Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer,” Current Medical Research and Opinion, vol. 31, no. 8, pp. 1573–1582, 2015. View at Publisher · View at Google Scholar
  • Jipan Xie, Yanni Hao, Nanxin Li, Peggy L. Lin, Erika Ohashi, Valerie Koo, and Eric Q. Wu, “Clinical outcomes among HR+/HER2− metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US,” Experimental Hematology & Oncology, vol. 4, no. 1, 2015. View at Publisher · View at Google Scholar
  • Marika Plöthner, Jan Zeidler, and Johann-Matthias Graf Von Der Schulenburg, “Individualized medicine in selected oncological diseases,” Public Health Forum, vol. 24, no. 2, pp. 131–134, 2016. View at Publisher · View at Google Scholar
  • Yanni Hao, Nanxin Li, Anna P. Fang, Valerie Koo, Miranda Peeples, Andrew Kageleiry, Eric Q. Wu, and Annie Guérin, “Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2− Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy,” Advances in Therapy, 2016. View at Publisher · View at Google Scholar
  • Annie Guérin, Yanni Hao, Derek Tang, Miranda Peeples, Anna Fang, Andrew Kageleiry, Valerie Koo, Nanxin Li, and Eric Q. Wu, “Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study,” Expert Opinion on Pharmacotherapy, pp. 1–8, 2016. View at Publisher · View at Google Scholar
  • Nanxin Li, Yanni Hao, Valerie Koo, Anna Fang, Miranda Peeples, Andrew Kageleiry, Eric Q. Wu, and Annie Guérin, “Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2− metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis,” Journal of Medical Economics, vol. 19, no. 4, pp. 414–423, 2016. View at Publisher · View at Google Scholar
  • Nanxin Li, Yanni Hao, Jipan Xie, Peggy L. Lin, Valerie Koo, Erika Ohashi, and Eric Q. Wu, “Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2− mBC Patients With Multiple Metastatic Sites,” Clinical Therapeutics, 2016. View at Publisher · View at Google Scholar
  • Nanxin Li, Yanni Hao, Andrew Kageleiry, Miranda Peeples, Anna Fang, Valerie Koo, Eric Q. Wu, and Annie Guérin, “Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US,” Current Medical Research and Opinion, vol. 32, no. 2, pp. 385–394, 2016. View at Publisher · View at Google Scholar
  • Giovanni Zanotti, Matthias Hunger, Julia J Perkins, Ruslan Horblyuk, and Monique Martin, “Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States,” BMC Cancer, vol. 17, no. 1, 2017. View at Publisher · View at Google Scholar
  • Pronzato Paolo, “Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer,” Future Oncology, 2017. View at Publisher · View at Google Scholar
  • Samantha K. Kurosky, Debanjali Mitra, Giovanni Zanotti, and James A. Kaye, “Treatment Patterns and Outcomes of Patients With Metastatic ER+/HER2- Breast Cancer: A Multicountry Retrospective Medical Record Review,” Clinical Breast Cancer, 2017. View at Publisher · View at Google Scholar
  • Monika Parisi, Corey Pelletier, Dasha Cherepanov, and Michael S Broder, “ Outcomes research examining treatments, quality of life and costs in HER2 -negative and triple-negative metastatic breast cancer: a systematic literature review ,” Journal of Comparative Effectiveness Research, 2018. View at Publisher · View at Google Scholar